Want to see AZTA full AI Analyst Report?
Top Page
Azenta
(NASDAQ:AZTA)
Select Model
Select Model
Rating:59Neutral
Price Target:
$34.00
▲(17.53% Upside)
Action:Reiterated
Date:08/25/26
AZTA’s score is driven by a strong, low-leverage balance sheet and a somewhat improving outlook from the latest earnings call (raised FY26 guidance and sequential EBITDA progress). These positives are tempered by continued lack of consistent profitability (negative TTM margins), volatile free cash flow, and near-term margin/FCF headwinds (gross margin pressure and remediation costs). Technically the stock is in an uptrend but appears overbought, while valuation metrics provide limited support due to the negative P/E and no dividend yield data.
Positive Factors
Recurring Revenue and Biorepository Growth
A large recurring revenue base improves visibility and customer retention, while biorepository utilization and consumables growth can support durable expansion beyond one-time instrument sales.
Negative Factors
Persistent Unprofitability
Sustained operating and net losses show that revenue has not yet translated into dependable earnings. This limits internally funded growth and leaves results sensitive to cost control, mix and execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue and Biorepository Growth
A large recurring revenue base improves visibility and customer retention, while biorepository utilization and consumables growth can support durable expansion beyond one-time instrument sales.
Read all positive factors
Azenta Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down sales across regions to show where Azenta earns most of its revenue, revealing exposure to regional biotech demand, regulatory environments, and currency swings. Heavy concentration in a few markets raises risk, while diversified or expanding geography points to broader adoption of its sample-management, cold chain and genomics offerings.
Breaks down sales across regions to show where Azenta earns most of its revenue, revealing exposure to regional biotech demand, regulatory environments, and currency swings. Heavy concentration in a few markets raises risk, while diversified or expanding geography points to broader adoption of its sample-management, cold chain and genomics offerings.
Data provided by:
The Fly
The FlyAzenta (AZTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.47B
Dividend YieldN/A
Average Volume (3M)965.29K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth1.47%
EPS Growth-9.38%
CountryUS
Employees2,900
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-2.75
Shares Outstanding43,808,390
10 Day Avg. Volume770,217
30 Day Avg. Volume965,289
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.00Price Target Upside20.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.39
Revenue Forecast (FY)$600.44M
Azenta Business Overview & Revenue Model
Company Description
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other interna...
How the Company Makes Money
Azenta makes money primarily by selling products and services that support the lifecycle of biological samples and genomics workflows. A major revenue stream comes from sample management solutions, which includes (1) sales of automated storage and...
Azenta Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.Positive Updates
Revenue Beat and Organic Growth
Total revenue of $161.0M in Q3, up 12% reported and 9% organically, ahead of company expectations.
Negative Updates
Overall and SMS Gross Margin Pressure
Total gross margin was 46.2%, down 140 basis points year-over-year. Sample Management Solutions gross margin declined sharply, to 45.9% for the quarter, down ~750 basis points versus prior year, driven by automated stores, cryogenic systems, unfavorable fixed cost absorption and quality remediation.
Read all updates
Q3-2026 Updates
Positive
Negative
Revenue Beat and Organic Growth
Total revenue of $161.0M in Q3, up 12% reported and 9% organically, ahead of company expectations.
Read all positive updates
Company Guidance
Azenta updated its fiscal 2026 outlook, now expecting reported revenue of $613–$618 million and organic revenue roughly flat to up 1% year‑over‑year (improved from prior -2% to +1%); full‑year adjusted EBITDA is guided to $59–$62 million (Q4 adjusted EBITDA $20–$23 million) with Q4 organic revenue expected to decline low single digits versus a tough Q4 comp. Management expects full‑year free cash flow to improve ~10%–15% YoY, anticipates UK Biocentre will dilute margins by ~30 basis points, and reiterated remediation costs for automated stores of ~$5–$6 million for FY26 (about $1 million incurred in Q3). For context, Q3 revenue was $161 million (up 12% reported / 9% organic), Q3 adjusted EBITDA margin was ~11.4% (down 60 bps YoY, up 610 bps sequential), gross margin was 46.2% (down 140 bps), cash and equivalents were $529 million, and the company repurchased ~2.3 million shares for $50 million while completing the $63 million divestiture of B Medical Systems.Azenta Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
78
Positive
Cash Flow
51
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 613.81M | 593.82M | 573.45M | 665.07M | 555.50M | 513.70M |
| Gross Profit | 270.37M | 270.28M | 254.62M | 233.26M | 230.62M | 214.51M |
| EBITDA | -96.62M | 54.07M | 71.62M | 55.15M | 48.35M | 9.94M |
| Net Income | -122.90M | -55.76M | -164.90M | -14.26M | -428.96M | 110.75M |
Balance Sheet | ||||||
| Total Assets | 1.88B | 2.06B | 2.10B | 2.89B | 3.72B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 325.80M | 340.92M | 462.09M | 1.02B | 1.57B | 227.51M |
| Total Debt | 53.97M | 111.17M | 70.68M | 60.44M | 49.23M | 94.77M |
| Total Liabilities | 366.08M | 330.70M | 331.07M | 351.22M | 352.74M | 494.18M |
| Stockholders Equity | 1.51B | 1.73B | 1.77B | 2.53B | 3.36B | 1.33B |
Cash Flow | ||||||
| Free Cash Flow | 9.88M | 38.32M | 12.35M | -33.60M | -543.48M | 97.05M |
| Operating Cash Flow | 37.98M | 72.18M | 49.74M | 5.83M | -466.05M | 149.86M |
| Investing Cash Flow | -72.43M | -90.46M | 224.74M | 431.38M | 1.47B | -146.35M |
| Financing Cash Flow | -51.16M | -9.59M | -659.21M | -840.46M | -62.76M | -25.91M |
Azenta Technical Analysis
Positive
28.93
Price Trends
28.68
Positive
25.42
Positive
28.26
Positive
Market Momentum
1.67
Positive
57.36
Neutral
28.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Positive. The current price of 28.93 is below the 20-day moving average (MA) of 32.98, above the 50-day MA of 28.68, and above the 200-day MA of 28.26, indicating a bullish trend. The MACD of 1.67 indicates Positive momentum. The RSI at 57.36 is Neutral, neither overbought nor oversold. The STOCH value of 28.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AZTA.
Azenta Risk Analysis
Azenta disclosed 35 risk factors in its most recent earnings report. Azenta reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azenta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.81B | 35.98 | 13.29% | ― | 0.17% | ― | |
69 Neutral | $2.45B | 232.19 | 2.14% | ― | 13.94% | ― | |
59 Neutral | $1.47B | -12.22 | -7.56% | ― | 1.47% | -9.38% | |
59 Neutral | $318.37M | -9.30 | -246.44% | ― | 12.93% | -219.19% | |
55 Neutral | $1.15B | 279.88 | 1.08% | ― | 51.30% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.02B | -0.99 | -55.30% | ― | -2.57% | -135.75% |
* Healthcare Sector Average
AZTA
Azenta
33.61
3.07
10.05%
ATRC
Atricure
49.27
12.28
33.20%
QDEL
QuidelOrtho
15.32
-13.37
-46.60%
STAA
Staar Surgical
22.39
-4.97
-18.17%
BLFS
BioLife Solutions
37.20
12.15
48.50%
SMTI
Sanara MedTech
34.58
0.92
2.73%
Azenta Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Azenta CEO Resigns as Interim Leader Reassures Outlook
Neutral
Aug 24, 2026
On August 22, 2026, Azenta announced that President and CEO John P. Marotta resigned from his executive roles and from the board, with the company stating his departure did not stem from any disagreement over operations or policies. The board simu...
Business Operations and StrategyM&A Transactions
Azenta Completes Strategic Divestiture to Streamline Portfolio
Positive
Jul 8, 2026
On July 1, 2026, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, completed the sale of the entire share capital of B Medical Systems S.à r.l. to Thelema S.à r.l. for a fixed purchase price of $63 million. The deal, originally a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.